









Markets
/
Stocks
/
nasdaq-btmd
/

Biote Corp

BTMD

2.870USD

+0.090+3.24%

Close 10/31, 16:00（ET）Quotes delayed by 15 min

90.96MMarket Cap

2.91P/E TTM



Biote Corp

2.870

+0.090+3.24%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Biote Corp

Currency: USD Updated: 2025-10-31

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Biote Corp's Score

Industry at a Glance

Industry Ranking

81 / 160

Overall Ranking

213 / 4618

Industry

Professional & Commercial Services

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

5.403

Target Price

+94.36%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Biote Corp Highlights

StrengthsRisks

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 19.54% year-on-year.

Undervalued

The company’s latest PE is 3.00, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 21.48M shares, decreasing 8.86% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.42M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.51.

Financial Health

Currency: USD Updated: 2025-10-31

The company's current financial score is 8.27, which is higher than the Professional & Commercial Services industry's average of 7.31. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 48.86M, representing a year-over-year decrease of 0.62%, while its net profit experienced a year-over-year decrease of 150.38%.

Score

Industry at a Glance

Previous score

8.27

Change



Financials

6.01

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.92

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.93

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.47

Key Metrics

Free cash flow

No Data

Biote Corp's Company Valuation

Currency: USD Updated: 2025-10-31

The company’s current valuation score is 5.92, which is lower than the Professional & Commercial Services industry's average of 7.13. Its current P/E ratio is 3.00, which is 6792.97% below the recent high of 206.76 and 1669.42% above the recent low of -47.08.

Score

Industry at a Glance

Previous score

5.92

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 81/160

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-31

The company’s current earnings forecast score is 8.00, which is higher than the Professional & Commercial Services industry's average of 7.67. The average price target for Biote Corp is 5.46, with a high of 8.00 and a low of 3.50.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 5 analysts

Buy

Current Rating

5.403

Target Price

+88.27%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Biote Corp

BTMD

S&P Global Inc

SPGI

Moody's Corp

MCO

Equifax Inc

EFX

TransUnion

TRU

MSCI Inc

MSCI

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-31

The company’s current price momentum score is 6.82, which is lower than the Professional & Commercial Services industry's average of 6.97. Sideways: Currently, the stock price is trading between the resistance level at 3.20 and the support level at 2.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.57

Change

0.25

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.002

Neutral

RSI(14)

46.566

Neutral

STOCH(KDJ)(9,3,3)

26.041

Neutral

ATR(14)

0.148

High Vlolatility

CCI(14)

-41.932

Neutral

Williams %R

63.934

Sell

TRIX(12,20)

-0.310

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.792

Buy

MA10

2.898

Sell

MA20

2.877

Sell

MA50

3.101

Sell

MA100

3.473

Sell

MA200

3.785

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-31

The company’s current institutional recognition score is 5.00, which is lower than the Professional & Commercial Services industry's average of 6.93. The latest institutional shareholding proportion is 64.54%, representing a quarter-over-quarter decrease of 16.26%. The largest institutional shareholder is The Vanguard, holding a total of 1.42M shares, representing 4.28% of shares outstanding, with 2.19% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Roystone Capital Management LP

4.62M

325 Capital LLC

4.55M

Heyer (Andrew R)

2.48M

-1.43%

Bandera Partners LLC

2.28M

-6.23%

BlackRock Institutional Trust Company, N.A.

1.61M

+3.62%

The Vanguard Group, Inc.

Star Investors

1.42M

+0.81%

Heyer (Steven J)

1.06M

Acadian Asset Management LLC

685.16K

-2.24%

Dimensional Fund Advisors, L.P.

617.59K

-5.31%

Geode Capital Management, L.L.C.

616.70K

+7.18%

Risk Assessment

Currency: USD Updated: 2025-10-31

The company’s current risk assessment score is 2.61, which is lower than the Professional & Commercial Services industry's average of 5.57. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.